Sign Out
The recommended starting dose is GLYXAMBI 10 mg/5 mg (empagliflozin 10 mg/linagliptin 5 mg) once daily. In patients tolerating GLYXAMBI 10 mg/5 mg once daily and requiring additional glycaemic control, the dose can be increased to GLYXAMBI 25 mg/5 mg (empagliflozin 25 mg/linagliptin 5 mg) once daily. GLYXAMBI can be taken with or without food and at any time of day.
Patients with renal impairment: GLYXAMBI is not recommended for use in patients with an eGFR less than 30 mL/min/1.73 m2 and contraindicated in patients on dialysis.
Patients with hepatic impairment: No dose adjustment is recommended for patients with hepatic impairment.
Elderly Patients: No dosage adjustment is recommended based on age. Therapeutic experience in patients aged 85 years and older is limited. Initiation of GLYXAMBI therapy in this population is not recommended (see Precautions).
Paediatric population: The safety and effectiveness of GLYXAMBI in children below 18 years of age have not been established. GLYXAMBI is not recommended for use in patients under 18 years of age.
Combination therapy: When GLYXAMBI is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see Interactions and Adverse Reactions).
Missed dose: If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.
